Lv13
30 积分 2023-05-17 加入
In Reference to: How Many Nodes to Take? Lymph Node Ratio Below 1/3 Reduces Papillary Thyroid Cancer Nodal Recurrence
6小时前
待确认
Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: Predictive factors and operative management
6小时前
已完结
ATA 2025: Less is more—Practical implications for the management of differentiated thyroid cancer
2天前
已完结
VALIDATION OF THE 2025 ATA RISK STRATIFICATION SYSTEM IN A COHORT OF PATIENTS WITH PAPILLARY THYROID CARCINOMA
2天前
求助中
Who leads, who treats, what dose? European paediatric differentiated thyroid carcinoma practice—an European Cooperative Study Group for Paediatric Rare Tumours survey
2天前
已完结
Letter to the editor: When Guidelines Meet Reality: Implementing the 2025 ATA Recommendations for Differentiated Thyroid Cancer in Limited-Resource Settings
2天前
已完结
Comparative review of contemporary guidelines for differentiated thyroid cancer management
2天前
已关闭
Intermediate‐Risk Papillary Thyroid Cancer: Not Everyone Needs Radioactive Iodine
2天前
已完结
Comparison of 2015 and 2025 ATA Risk Stratification Systems for Predicting Recurrence in Papillary Thyroid Carcinoma
2天前
已完结
皖公网安备34019202002308
